Cel-Sci (NYSEAMERICAN:CVM) Stock Price Down 2.1% – Should You Sell?

Cel-Sci Corporation (NYSEAMERICAN:CVM) shares traded down 2.1% during trading on Wednesday. The company traded as low as $1.38 and last traded at $1.38. 27,787 shares changed hands during mid-day trading, a decline of 85% from the average daily volume of 183,912 shares. The stock had previously closed at $1.41.

Cel-Sci Stock Performance

The company’s 50-day simple moving average is $1.69 and its 200-day simple moving average is $2.45. The stock has a market capitalization of $25.35 million, a price-to-earnings ratio of -0.15 and a beta of 0.62. The company has a current ratio of 1.48, a quick ratio of 1.42 and a debt-to-equity ratio of 0.35.

Cel-Sci (NYSEAMERICAN:CVM) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.47) EPS for the quarter.

Institutional Trading of Cel-Sci

An institutional investor recently raised its stake in Cel-Sci stock. Renaissance Technologies LLC increased its stake in Cel-Sci Corporation (NYSEAMERICAN:CVM) by 133.0% during the first quarter, according to its most recent filing with the SEC. The fund owned 35,890 shares of the company’s stock after buying an additional 20,484 shares during the quarter. Renaissance Technologies LLC owned 0.42% of Cel-Sci worth $115,000 at the end of the most recent quarter. Institutional investors own 12.08% of the company’s stock.

Cel-Sci Company Profile

Cel-Sci Corporation is a biotechnology company focused on developing investigational immunotherapies for cancer and infectious diseases. The company’s lead product candidate, Multikine (leukocyte interleukin, injection), is designed to stimulate and coordinate the immune system’s response to cancer. It has primarily been studied as a potential treatment for locally advanced primary head and neck cancer and is not an approved commercial therapy.

Cel-Sci also develops treatments using its proprietary LEAPS (L.E.A.P.S.) technology platform, which is intended to direct immune responses against specific disease-related targets.